Type of lymphoma | Outcome | Cellular functions, mechanisms, and clinical consequence | References |
---|---|---|---|
B cell-derived | Unfavorable | Enhanced metastasis in vivo | [15] |
DLBCL | Favorable |  ▪ Increase survival of patients  ▪ c-MET retained the physiologic growth control  ▪ c-MET(+) DLBCL was more proliferated and more responsive to therapy  ▪ c-MET directly binds to the pro-apoptotic protein FAS | |
Primary intestinal DLBCL | Unfavorable | Reduce survival of patients | [19] |
DLBCL | Unfavorable |  ▪ Increase the activities of MEK-MAPK  ▪ Increase the activities of PI3K-PKB/AKT and its substrates GSK3 and FOXO3a  ▪ Inhibition of fatty acid synthase | |
PEL | Unfavorable | Required for tumor progression in xenograft model | [37] |
BL | Unfavorable |  ▪ Protection of cells from apoptosis  ▪ Activation of MAPK  ▪ Induce drug resistance of tumor cells | |
MALT | Unfavorable | Required for tumor cell proliferation/growth | [41] |
cHL | Favorable | Increase survival of patients | |
cHL | Unfavorable | Increase the relapse | [47] |
ALCL | Unfavorable | Required for tumor progression | [48] |
NKTCL | Unfavorable | Required for tumor cell proliferation | [49] |
TLL | Unfavorable | Required for tumor progression |